Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF‐κB pathway
Sign Up to like & getrecommendations! Published in 2022 at "Cell Proliferation"
DOI: 10.1111/cpr.13291
Abstract: The main target of current drugs for alleviating bone loss is osteoclasts. However, the long‐term application of such drugs will also cause side effects. Therefore, it is of great need to develop new and safer… read more here.
Keywords: urolithin suppressed; osteoclast activation; loss; bone loss ... See more keywords